Virtual lab model for the generation of novel natural product derived therapeutics

There exists a pressing need for new therapeutics to solve a number of threats to human health, including multidrug resistant bacteria and cancer. Although a number of promising biotechnologies developed in the UK hold great promise for solving these critical problems, few biotechnology companies achieve commercial success. Acidophil Ltd is pursuing an innovative virtual company model to exploit existing academic and commercial capabilities to combine synthetic biology with synthetic chemistry for the development of novel therapeutics. This business model is aimed towards decreasing the time and cost of developing novel patent protected therapeutics. The project will allow for further development and evaluation of Acidophil’s business model and a comparison to the models used by competing companies.